OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial

NCT05587894 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

256

Enrollment

OTHER_GOV

Sponsor class

Conditions

COVID-19
Immunodeficiency

Interventions

DRUG: Paxlovid 5 days
DRUG: Paxlovid 10 days
DRUG: Veklury

Sponsor

ANRS, Emerging Infectious Diseases